-
公开(公告)号：US20140086923A1
公开(公告)日：2014-03-27
申请号：US14008423
申请日：2012-03-29
IPC分类号： C07K16/28 , G01N33/569
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/28 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/57415
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
摘要翻译： 本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。 本发明还提供了针对ICOS或其衍生物的抗体，其诱导IL-10和IFNγ产生，诱导CD4 + T细胞增殖，降低Tconv增殖，并增加Treg的免疫抑制功能。
-
公开(公告)号：US09376493B2
公开(公告)日：2016-06-28
申请号：US14008423
申请日：2012-03-29
IPC分类号： C07K16/28 , A61K39/395 , G01N33/569
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/28 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/56972 , G01N33/57415
摘要： The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
摘要翻译： 本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。 本发明还提供了针对ICOS或其衍生物的抗体，其诱导IL-10和IFNγ产生，诱导CD4 + T细胞增殖，降低Tconv增殖，并增加Treg的免疫抑制功能。
-
3.发明申请Use of the Combinatorial Diversity of T-Lymphocyte Repertoire as a Prognostic Marker of Cancer 审中-公开T淋巴细胞谱系组合多样性的使用作为癌症的预后标记公开(公告)号：US20120309013A1
公开(公告)日：2012-12-06
申请号：US13514842
申请日：2010-12-09
申请人： Christophe Caux , Jean-François Mouret , Christine Menetrier-Caux , Nicolas Pasqual , Thomas Bachelot , Manuarii Manuel , Jean-Yves Blay
发明人： Christophe Caux , Jean-François Mouret , Christine Menetrier-Caux , Nicolas Pasqual , Thomas Bachelot , Manuarii Manuel , Jean-Yves Blay
IPC分类号： G01N21/76
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/16
摘要： The present invention relates to a method making it possible to identify the patients, from among those affected by a given solid cancer, that have increased risk of premature death. Said method is based on the ex vivo analysis of the lymphocytic diversity of the patients on the basis of a biological sample containing lymphocytes. In fact, low lymphocytic diversity is related to a poor prognosis. Specifically, it is possible to set a diversity threshold, depending on the analysis technology used and the cancer affecting the patient, beyond which the life expectancy of the patient is significantly less than that, in general, of the patients affected by the same disease.
摘要翻译： 本发明涉及一种使得可能鉴定出患有早期死亡风险增加的患者，从受到特定实体癌症影响的患者中。 所述方法基于在含有淋巴细胞的生物样品的基础上对患者的淋巴细胞多样性的离体分析。 事实上，低淋巴细胞多样性与预后不良有关。 具体地，可以根据所使用的分析技术和影响患者的癌症来设定多样性阈值，超过该阈值的患者的预期寿命明显低于一般受同一疾病影响的患者的预期寿命。
-
公开(公告)号：US20100086560A1
公开(公告)日：2010-04-08
申请号：US12536542
申请日：2009-08-06
申请人： Christophe Caux , Beatrice Vanbervliet , Carine Paturel , Alain Vicari , Giorgio Trinchieri , Francine Briere , Nathalie Bendriss
发明人： Christophe Caux , Beatrice Vanbervliet , Carine Paturel , Alain Vicari , Giorgio Trinchieri , Francine Briere , Nathalie Bendriss
IPC分类号： A61K39/00
CPC分类号： A61K39/39 , A61K38/191 , A61K38/195 , A61K38/202 , A61K38/212 , A61K2039/55511 , A61K2039/55522 , A61K2300/00
摘要： Dendritic cells play a critical role in antigen-specific immune responses. Materials and Methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC). In particular, methods for treating disease states are provided comprising administration of chemokine receptor agonists and antagonists, alone or in combination with a disease-associated antigen, with or without an activating agent.
摘要翻译： 树突状细胞在抗原特异性免疫应答中起关键作用。 提供材料和方法用于通过促进或抑制称为浆细胞样树突状细胞（pDC）的抗原呈递树突状细胞的特定子集的迁移或活化来治疗疾病状态，包括癌症，感染性疾病，自身免疫疾病，移植和变态反应。 特别地，提供了用于治疗疾病状态的方法，其包括单独或与疾病相关抗原组合施用趋化因子受体激动剂和拮抗剂，具有或不具有活化剂。
-
公开(公告)号：US06271014B1
公开(公告)日：2001-08-07
申请号：US09211704
申请日：1998-12-14
IPC分类号： C12N950
CPC分类号： C12N9/6491 , C07K2319/00 , C12N7/00
摘要： Nucleic acids encoding various proteases, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
摘要翻译： 描述了编码来自哺乳动物的各种蛋白酶，与其相关的试剂（包括特异性抗体）和纯化的蛋白质的核酸。 还提供了使用所述试剂和相关诊断试剂盒的方法。
-
6.发明授权Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors 失效在筛选测定中使用嵌合受体鉴定细胞受体的激动剂和拮抗剂公开(公告)号：US07700728B2
公开(公告)日：2010-04-20
申请号：US11388884
申请日：2006-03-24
CPC分类号： G01N33/5008 , C07K14/705 , C07K14/70503 , C12N15/62 , G01N33/502 , G01N33/5044 , G01N33/566 , G01N2333/705
摘要： The present invention provides novel materials and screening methods for identifying agonists and antagonists of cell receptors. Methods are disclosed for identifying agonists and antagonists using chimeric receptors comprising the extracellular ligand-binding domain of a first receptor fused with the transmembrane and intracellular domains of a second receptor containing an intracellular immunoreceptor tyrosine-based activation motif (ITAM).
摘要翻译： 本发明提供用于鉴定细胞受体的激动剂和拮抗剂的新型材料和筛选方法。 公开了用于鉴定激动剂和拮抗剂的方法，所述嵌合受体包含与含有细胞内免疫受体酪氨酸的活化基序（ITAM）的第二受体的跨膜和胞内结构域融合的第一受体的细胞外配体结合结构域。
-
公开(公告)号：US07217700B2
公开(公告)日：2007-05-15
申请号：US09768917
申请日：2001-01-24
申请人： Alain P. Vicari , Christophe Caux
发明人： Alain P. Vicari , Christophe Caux
CPC分类号： A61K39/0011 , A61K38/1709 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/2026 , A61K2039/53 , A61K2039/55522 , A61K2300/00
摘要： Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.
摘要翻译： 树突状细胞在抗原特异性免疫应答中起关键作用。 通过促进或抑制抗原呈递树突状细胞的迁移或活化，提供了用于治疗疾病状态（包括癌症和自身免疫性疾病）的材料和方法。 特别地，趋化因子用于引发，扩增或调节免疫应答。 在一个实施方案中，趋化因子用于将树突细胞吸引至抗原递送部位。 抗原递送部位的树突数增加意味着更多的抗原摄取和修饰的免疫应答。
-
公开(公告)号：US06361939B1
公开(公告)日：2002-03-26
申请号：US08978289
申请日：1997-11-25
申请人： Elizabeth Esther Mary Bates , Blandine Marie de Saint-Vis , Christophe Caux , Serge J. E. Lebecque , Jacques Banchereau
发明人： Elizabeth Esther Mary Bates , Blandine Marie de Saint-Vis , Christophe Caux , Serge J. E. Lebecque , Jacques Banchereau
IPC分类号： C07H2104
CPC分类号： C07K14/70503 , C07K2319/00 , Y10S435/975
摘要： Polynucleotides encoding various dendritic cell specific proteins from a primate are provided. Uses of purified sequences are also disclosed, including producing related reagents, e.g., specific antibodies, and purified proteins. Methods of using these reagents and related diagnostic kits are also described.
摘要翻译： 提供了从灵长类动物编码各种树突状细胞特异性蛋白质的多核苷酸。 还公开了纯化序列的用途，包括产生相关试剂，例如特异性抗体和纯化的蛋白质。 还描述了使用这些试剂和相关诊断试剂盒的方法。
-
公开(公告)号：US20070128159A1
公开(公告)日：2007-06-07
申请号：US11626667
申请日：2007-01-24
申请人： Alain Vicari , Christophe Caux , Drake LaFace
发明人： Alain Vicari , Christophe Caux , Drake LaFace
IPC分类号： A61K38/19
CPC分类号： A61K39/0011 , A61K38/1709 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/2026 , A61K2039/53 , A61K2039/55522 , A61K2300/00
摘要： Dendritc cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.
摘要翻译： 树突状细胞在抗原特异性免疫应答中起关键作用。 通过促进或抑制抗原呈递树突状细胞的迁移或活化，提供了用于治疗疾病状态（包括癌症和自身免疫性疾病）的材料和方法。 特别地，趋化因子用于引发，扩增或调节免疫应答。 在一个实施方案中，趋化因子用于将树突细胞吸引至抗原递送部位。 抗原递送部位的树突数增加意味着更多的抗原摄取和修饰的免疫应答。
-
公开(公告)号：US06812004B1
公开(公告)日：2004-11-02
申请号：US08799028
申请日：1997-02-10
IPC分类号： C12N1519
CPC分类号： C07K14/523 , C07K2319/00
摘要： A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. Methods of using said reagents and diagnostic kits are also provided.
摘要翻译： 来自哺乳动物的新型CC趋化因子，与其相关的试剂，包括纯化的蛋白质，特异性抗体和编码所述趋化因子的核酸。 还提供了使用所述试剂和诊断试剂盒的方法。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.023 秒)